Fra-2 controls the response to the KRAS inhibitor MRTX-1133 in pancreatic ductal adenocarcinoma.

doi:10.1073/pnas.2601788123

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Fra-2 controls the response to the KRAS inhibitor MRTX-1133 in pancreatic ductal adenocarcinoma.

Proceedings of the National Academy of Sciences of the United States of America - 5 May 2026

Testa Erika, Dezi Clara, Lovat Francesca, Piro Geny, Carbone Carmine, Capece Marina, Nigita Giovanni, Putro Erisa, Renzi Elisabetta Di, Simeone Alessandra, Bonetti Luca Reggiani, Cirombella Roberto, Magistri Paolo, Corbo Vincenzo, Pasini Davide, Belletti Barbara, Baldassarre Gustavo, Vecchione Andrea, Croce Carlo M, Rampioni Vinciguerra Gian Luca

Abstract excerpt

KRAS mutations are a hallmark of pancreatic ductal adenocarcinoma (PDAC), driving tumor initiation and progression in the vast majority of cases, with KRASG12D being the most prevalent variant. Recent advances have led to the development of mutation-specific KRAS inhibitors (KRASi), yet their clinical impact is hindered by the rapid onset of drug resistance. In this study, we identify Fos-related antigen-2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Pancreatic Ductal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Line, Tumor

Share to Drug Resistance, Neoplasm

Share to Gene Expression Regulation, Neoplastic

Share to Pancreatic Neoplasms

Share to Proto-Oncogene Proteins p21(ras)

Share to TOR Serine-Threonine Kinases

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 42054368
DOI: 10.1073/pnas.2601788123
PMCID: PMC13142990

Genes

KRAS
MTOR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Fra-2 controls the response to the KRAS inhibitor MRTX-1133 in pancreatic ductal adenocarcinoma.PMID 42054368Read ↗

AP1/Fra1 confers resistance to MAPK cascade inhibition in pancreatic cancer.Semantic proximity Read ↗

An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer.Semantic proximity Read ↗

Nutrient restriction-activated Fra-2 promotes tumor progression via IGF1R in miR-15a downmodulated pancreatic ductal adenocarcinomaSemantic proximity Read ↗

Resistance to the KRAS <sup>G12D</sup> Inhibitor MRTX1133 is Associated with Increased Sensitivity to BET InhibitionSemantic proximity Read ↗

KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer.Semantic proximity Read ↗

KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of TherapySemantic proximity Read ↗

KRAS-dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS InhibitorsSemantic proximity Read ↗

Treatment of KRAS-Mutated Pancreatic Cancer: New Hope for the Patients?Semantic proximity Read ↗

An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancer.Semantic proximity Read ↗

Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survivalSemantic proximity Read ↗

Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer.Semantic proximity Read ↗

Characterization and therapeutic suppression of KEAP1-NRF2-driven resistance to KRAS inhibitors in pancreatic and lung cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.